Biomea Fusion Investor Relations Material
Latest events
Status Update
Biomea Fusion
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Biomea Fusion Inc
Access all reports
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of covalent small molecule drugs. These drugs are designed to treat patients with genetically defined cancers and metabolic diseases. The company’s approach leverages covalent bonding, where a small molecule forms a permanent bond with its target protein, which may offer advantages like greater target selectivity and a more durable therapeutic response. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.
Key slides for Biomea Fusion Inc
Status Update
Biomea Fusion Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Biomea Fusion Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
BMEA
Country
🇺🇸 United States